Sonendo, Inc. (SONX)
USD 1.15
(-14.81%)
USD 1.15
(-14.81%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -57.74 Million USD | 0.79% |
| 2022 | -58.2 Million USD | -31.84% |
| 2021 | -44.14 Million USD | -2.02% |
| 2020 | -43.27 Million USD | 4.81% |
| 2019 | -45.45 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -10.24 Million USD | -3.71% |
| 2024 Q2 | -6.67 Million USD | 34.9% |
| 2023 Q1 | -14.81 Million USD | -0.35% |
| 2023 FY | -57.74 Million USD | 0.79% |
| 2023 Q4 | -9.88 Million USD | 38.61% |
| 2023 Q2 | -16.95 Million USD | -14.43% |
| 2023 Q3 | -16.09 Million USD | 5.04% |
| 2022 Q4 | -14.76 Million USD | -1.14% |
| 2022 Q3 | -14.59 Million USD | -2.16% |
| 2022 Q2 | -14.28 Million USD | 1.85% |
| 2022 Q1 | -14.55 Million USD | -7.28% |
| 2022 FY | -58.2 Million USD | -31.84% |
| 2021 Q1 | -9.84 Million USD | 13.91% |
| 2021 FY | -44.14 Million USD | -2.02% |
| 2021 Q4 | -13.56 Million USD | -22.26% |
| 2021 Q3 | -11.09 Million USD | -12.12% |
| 2021 Q2 | -9.89 Million USD | -0.57% |
| 2020 Q2 | -11.16 Million USD | 0.0% |
| 2020 Q1 | -11.16 Million USD | 0.0% |
| 2020 FY | -43.27 Million USD | 4.81% |
| 2020 Q4 | -11.43 Million USD | -19.69% |
| 2020 Q3 | -9.55 Million USD | 14.43% |
| 2019 FY | -45.45 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acutus Medical, Inc. | -14.36 Million USD | -302.082% |
| Biotricity, Inc. | -8.82 Million USD | -554.069% |
| Cell MedX Corp. | -313.43 Thousand USD | -18322.933% |
| Dynatronics Corporation | -2.27 Million USD | -2440.334% |
| Nemaura Medical Inc. | -9.59 Million USD | -501.788% |
| PetVivo Holdings, Inc. | -10.62 Million USD | -443.651% |
| RetinalGenix Technologies Inc. | -2.08 Million USD | -2666.729% |
| Telesis Bio, Inc. | -35.15 Million USD | -64.276% |
| Talis Biomedical Corporation | -66.81 Million USD | 13.578% |
| Viveve Medical, Inc. | -21.55 Million USD | -167.912% |